The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.

(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s ...

Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible. In October, the FDA issued the clinical hold due to a spontaneous ...

Novavax’s COVID-19 vaccine produced higher ... There are 26 potential vaccine candidates in clinical trials, according to the World Health Organization’s reckoning, with the most advanced ...

However, recent news represents a setback for Novavax's combined vaccine candidate. The U.S. Food and Drug Administration (FDA) ordered a temporary halt to the program and to the company's stand ...

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...